Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma

Respiratory Medicine

Volumn 109, Issue 3, 2015, Pages 329-338

  Timmer, Wolfgang ^a   Moroni Zentgraf, Petra ^b   Cornelissen, Piet ^b   Unseld, Anna ^b   Pizzichini, Emilio ^c   Buhl, Roland ^d  

^a CRS Clinical Research Services Mannheim GmbH   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Anticholinergic drug; Asthma; Bronchodilator efficacy; Dosing regimen; Long acting bronchodilator; Tiotropium

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; BRONCHODILATATION; CONTROLLED STUDY; CONTUSION; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DISEASE DURATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY NOSE; DRY THROAT; DYSPHONIA; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; GASTROENTERITIS; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PEAK EXPIRATORY FLOW; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SINUS TACHYCARDIA; SINUSITIS; SOFT MIST INHALER; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; URINARY EXCRETION; VIRAL RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA; ADOLESCENT; AGED; AUSTRIA; CLINICAL TRIAL; COMPARATIVE STUDY; CZECH REPUBLIC; DOSE RESPONSE; DRUG EFFECTS; ESTONIA; GERMANY; INHALATIONAL DRUG ADMINISTRATION; LATVIA; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ASTHMA; AUSTRIA; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; CZECH REPUBLIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ESTONIA; FEMALE; FORCED EXPIRATORY VOLUME; GERMANY; HUMANS; LATVIA; MALE; MIDDLE AGED; RISK FACTORS; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84933179804     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.12.005     Document Type: Article

References (20)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2014. Revised 2014. Available from: http://www.ginasthma.org/local/uploads/files/GINA-Report-2014-Aug12.pdf [accessed 21.11.14].
2. National Heart, Lung, and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma. National Asthma Education and Prevention Program; 2007. Full Report 2007. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf [accessed 15.07.14].
3. British Thoracic Society. British guideline on the management of asthma. A national clinical guideline; 2012. Available from: http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf [accessed 16.04.14].
4. Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cros-ssectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012;21:66-74.
5. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13. http://dx.doi.org/10.1186/1471-2466-6-13.
6. Rabe KF, Adachi M, Lai CKW, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity and control of asthma in children and adults: the global Asthma Insights and Reality surveys. J Allergy Clin Immunol 2004;114:40-7.
7. Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010;363:1715-26. http://dx.doi.org/10.1056/NEJMoa1008770.
8. Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 2011;128:315-22. http://dx.doi.org/10.1016/j.jaci.2011.06.004.
9. Kerstjens HAM, Disse B, Schröder-Babo W, Bantje TA, Gahlemann M, Sigmund R, et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011;128:308-14. http://dx.doi.org/10.1016/j.jaci.2011.04.039.
10. Kerstjens HAM, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012;367:1198-207. http://dx.doi.org/10.1056/NEJMoa1208606.
11. Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Unseld A, Engel M, et al. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respir Res 2014;15:61. http://dx.doi.org/10.1186/1465-9921-15-61.
12. Kerstjens HAM, Bleecker E, Meltzer E, Casale T, Pizzichini E, Schmidt O, et al. Tiotropium as add-on to inhaled corticosteroids significantly improves asthma control as reflected by the ACQ responder rate. Eur Respir J 2013;42(Suppl 57):876s (abs 4130).
13. Kerstjens HAM, Bleecker E, Meltzer E, Casale T, Pizzichini E, Schmidt O, et al. Tiotropium as add-on therapy to inhaled corticosteroids for patients with symptomatic asthma: lung function and safety. Eur Respir J 2013;42(Suppl 57):980s (abs 4629).
14. FitzGerald JM, Kerstjens H, Paggiaro P, Ohta K, Ichinose M, Moroni-Zentgraf P, et al. Once-daily tiotropium Respimat addon to ICS±LABA improves control across asthma severities. Eur Respir J 2014;44(Suppl 58) (abs 1864).
15. Lötvall J, Bateman ED, Bleecker ER, Busse WW, Woodcock A, Follows R, et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J 2012;40:570-9.
16. 2 agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med 2012;106:1110-5.
17. Postma D, Anzueto A, Calverley P, Jenkins C, Make BJ, Sciurba FC, et al. A new perspective on optimal care for patients with COPD. Prim Care Respir J 2011;20:205-9. http://dx.doi.org/10.4104/pcrj.2011.00041.
18. Mallol J, Aguirre V. Once versus twice daily budesonide metered-dose inhaler in children with mild to moderate asthma: effect on symptoms and bronchial responsiveness. Allergol Immunopathol Madr 2007;35:25-31.
19. Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010;10:1.
20. Guest JF, Davie AM, Ruiz FJ, Greener MJ. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J 2005;14:88-98.